Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine (1459)
Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available
10.1212/wnl.96.15_supplement.1459